Interpreting clinical assays for histone deacetylase inhibitors

References

• ChoudhuriSCuiYKlaassenCDMolecular targets of epigenetic regulation and effectors of environmental influencesToxicol Appl Pharmacol2010245337839320381512
   PubMed Web of Science ®Google Scholar
• Santos-RosaHCaldasCChromatin modifier enzymes, the histone code and cancerEur J Cancer200541162381240216226460
   PubMed Web of Science ®Google Scholar
• OliverSSDenuJMDynamic interplay between histone H3 modifications and protein interpreters: emerging evidence for a “histone language”Chembiochem201112229930721243717
   PubMed Web of Science ®Google Scholar
• ZeeBMLevinRSDimaggioPAGlobal turnover of histone post-translational modifications and variants in human cellsEpigenetics Chromatin20103223321134274
   PubMed Web of Science ®Google Scholar
• DekkerFHaismaHJHistone acetyl transferases as emerging drug targetsDrug Discovery Today20091419/2094294819577000
   PubMed Web of Science ®Google Scholar
• LimSMetzgerESchüleREpigenetic regulation of cancer growth by histone demethylasesInt J Cancer201012791991199820607829
   PubMed Web of Science ®Google Scholar
• NicholsonTBChenTRichardSThe physiological and pathophysiological role of PRMT1-mediated protein arginine methylationPharmacol Res200960646647419643181
   PubMed Web of Science ®Google Scholar
• FackelmayerFOProtein arginine methyltransferases: guardians of the Arg?Trends Biochem Sci2005301266667116257219
   PubMed Web of Science ®Google Scholar
• TiniMNaeemHTorchiaJBiochemical analysis of arginine methylation in transcriptionMethods Mol Biol200952323524719381935
   PubMedGoogle Scholar
• SpannhoffATHauserRHeinkeWThe emerging therapeutic potential of histone methyltransferase and demethylase inhibitorsChemMedChem20094101568158219739196
   PubMed Web of Science ®Google Scholar
• ZhangYXuKNiMNucleosome dynamics define transcriptional enhancersNature Genetics201042434334720208536
   PubMed Web of Science ®Google Scholar
• CopelandRAOlhavaEJScottMPTargeting epigenetic enzymes for drug discoveryCurr Opin Chem Biol201014450551020621549
   PubMed Web of Science ®Google Scholar
• JonesPABaylinSBThe fundamental role of epigenetic events in cancerNat Rev Genet20023641542812042769
   PubMed Web of Science ®Google Scholar
• KriaucionisSHeintzNThe nuclear DNA base 5-hydroxymethylcytosine is present in purkinje neurons and the brainScience2009324592992993019372393
   PubMed Web of Science ®Google Scholar
• Abdel-WahabOMullallyAHedvatCGenetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesBlood2009114114414719420352
   PubMed Web of Science ®Google Scholar
• FabbriMCalinGAEpigenetics and miRNAs in human cancerAdv Genet201070879920920746
   PubMed Web of Science ®Google Scholar
• ZainJKaminetzkiDO’ConnorOAEmerging role of epigenetic therapies in cutaneous T-cell lymphomasExpert Rev Hematol20103218720321083462
   PubMed Web of Science ®Google Scholar
• GrahamJSKayeSBBrownRThe promises and pitfalls of epigenetic therapies in solid tumorsEur J Cancer20094571129113619211243
   PubMed Web of Science ®Google Scholar
• BoldenJEPeartMJJohnstoneRWAnticancer activities of histone deacetylase inhibitorsNat Rev Drug Discov20065957695784
   Web of Science ®Google Scholar
• HaberlandMMontgomeryRLOlsonENThe many roles of histone deacetylases in development and physiology: implications for disease and therapyNat Rev Genet2009101324219065135
   PubMed Web of Science ®Google Scholar
• RazidloDFWhitneyTJCasperMEHistone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fatPLoS One201057e1149220628553
   PubMed Web of Science ®Google Scholar
• BhaskaraSChylaBJAmannJMDeletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage controlMol Cell2008301617218406327
   PubMed Web of Science ®Google Scholar
• De ZoetenEFWangLSaiHInhibition of HDAC9 increases T regulatory cell function and prevents colitis in miceGastroenterology2010138258359419879272
   PubMed Web of Science ®Google Scholar
• KotianSLiyanarachchiSZelentAHistone deacetylases 9 and 10 are required for homologous recombinationJ Biol Chem. Epub 2011 Jan 18.
   Google Scholar
• KellyGA review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1Altern Med Rev201015324526321155626
   PubMedGoogle Scholar
• ZhangYKwonSYamaguchiTMice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normallyMol Cell Biol20082851688170118180281
   PubMed Web of Science ®Google Scholar
• MaiAAltucciLEpi-drugs to fight cancer: from chemistry to cancer treatment, the road aheadInt J Biochem Cell Biol200941119921318790076
   PubMed Web of Science ®Google Scholar
• MarksPADokmanovicMHistone deacetylase inhibitors: discovery and development as anticancer agentsExpert Opin Investig Drugs2005141214971511
   PubMed Web of Science ®Google Scholar
• BertrandPInside HDAC with HDAC inhibitorsEur J Med Chem20104562095211620223566
   PubMed Web of Science ®Google Scholar
• Yurek-GeorgeACecilARMoAHThe first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitorJ Med Chem200750235720572617958342
   PubMed Web of Science ®Google Scholar
• KhanNJeffersMKumarSDetermination of the class and isoform selectivity of small-molecule histone deacetylase inhibitorsBiochem J2008409258158917868033
   PubMed Web of Science ®Google Scholar
• KrennHrubecKMarshallBLHedglinMDesign and evaluation of ‘linkerless’ hydroxamic acids as selective HDAC8 inhibitorsBioorg Med Chem Lett200717102874287817346959
   PubMed Web of Science ®Google Scholar
• EstiuGGreenbergEHarrisonCBStructural origin of selectivity in class II-selective histone deacetylase inhibitorsJ Med Chem200851102898290618412327
   PubMed Web of Science ®Google Scholar
• TaoriKPaulVJLueschHStructure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca spJ Am Chem Soc200813061806180718205365
   PubMed Web of Science ®Google Scholar
• HuhtiniemiTSuuronenTLahtela-KakkonenMNε-Modified lysine containing inhibitors for SIRT1 and SIRT2Bioorg Med Chem201018155616562520630764
   PubMed Web of Science ®Google Scholar
• HuhtiniemiTWittekindtCLaitinenTComparative and pharmacophore model for deacetylase SIRT1J Comput Aided Mol Des200620958959917103016
   PubMed Web of Science ®Google Scholar
• ElautGTörökGVinkenMMajor phase I biotransformation pathways of Trichostatin A in rat hepatocytes and in rat and human liver microsomesDrug Metab Dispos200230121320132812433798
   PubMed Web of Science ®Google Scholar
• EbbelENLeymarieNSchiavoSIdentification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometryAnalytical Biochem20103992152161
   PubMed Web of Science ®Google Scholar
• PariseRAHolleranJLBeunerJHA liquid chromatography–electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serumJ Chrom B20068402108115
   PubMed Web of Science ®Google Scholar
• DuLMussonDGWangAQStability studies of vorinostat and its two metabolites in human plasma, serum and urineJ Pharm Biomed Anal200642555656416824724
   PubMed Web of Science ®Google Scholar
• FurumaiRMatsuyamaAKobashiNFK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylasesCancer Res200262174916492112208741
   PubMed Web of Science ®Google Scholar
• XiaoJJByrdJMarcucciGIdentification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the bloodRapid Commun Mass Spectrom200317875776612672127
   PubMed Web of Science ®Google Scholar
• ShiragaTTozukaZIshimuraRIdentification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomesBiol Pharm Bull200528112412915635176
   PubMed Web of Science ®Google Scholar
• KimHMOhSJParkSKIn vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serumXenobiotica200838328129318274957
   PubMed Web of Science ®Google Scholar
• FonsiMFioreFJonesPMetabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fateXenobiotica2009391072273719569735
   PubMed Web of Science ®Google Scholar
• PeartMJSmythGKvan LaarRKIdentification and functional significance of genes regulated by structurally different histone deacetylase inhibitorsPNAS2005102103697370215738394
   PubMed Web of Science ®Google Scholar
• EllisLPanYSmythGKHistone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaClin Cancer Res200814144500451018628465
   PubMed Web of Science ®Google Scholar
• KatoNTanakaJSugitaJRegulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cellsLeukemia200721102103210817625602
   PubMed Web of Science ®Google Scholar
• VoDDPrinsRMBegleyJLEnhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824Cancer Res200969228693869919861533
   PubMed Web of Science ®Google Scholar
• CameronEEBachmanKEMyöhänenSSynergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancerNat Genet19992111031079916800
   PubMed Web of Science ®Google Scholar
• AppelbaumFRBaerMRCarabasiMHNCCN Practice guidelines for acute myelogenous leukemiaOncology20001411A536111195419
   PubMed Web of Science ®Google Scholar
• SnykersSVinkenMRogiersVDifferential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapyArch Toxicol200781853354417387455
   PubMed Web of Science ®Google Scholar
• MarksPAMillerTRichonVMHistone deacetylasesCurr Opin Pharmacol20033434435112901942
   PubMed Web of Science ®Google Scholar
• DiGiuseppeJAWengLJYuKHPhenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysisLeukemia19991381243125310450753
   PubMed Web of Science ®Google Scholar
• CarducciMANelsonJBChan-TackKMPhenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetateClin Cancer Res1996223793879816181
   PubMed Web of Science ®Google Scholar
• ZhangXWeiLYangYYuQSodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathwayJ Cell Biochem200493481982915389886
   PubMed Web of Science ®Google Scholar
• GorospeMShackSGuytonKZUp-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetateCell Growth Differ1996712160916158959328
   PubMedGoogle Scholar
• LiuLHudginsWRMillerACTranscriptional upregulation of TGF-α by phenylacetate and phenylbuytrate is associated with differentiation of human melanoma cellsCytokine1995754494567578983
   PubMed Web of Science ®Google Scholar
• HanSWadaRKSidellNDifferentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferatoractivated receptor gammaCancer Res200161103998400211358817
   PubMed Web of Science ®Google Scholar
• CarducciMANelsonJBChan-TackKMPhenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetateClin Cancer Res1996223793879816181
   PubMed Web of Science ®Google Scholar
• BrusilowSWPhenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretionPediatr Res19912921471502014149
   PubMed Web of Science ®Google Scholar
• PhuphanichSBakerSDGrossmanSAOral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic studyNeuro Oncol20057217718215831235
   PubMed Web of Science ®Google Scholar
• CarducciMAGilbertJBowlingMKA phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion scheduleClin Cancer Res20017103047305511595694
   PubMed Web of Science ®Google Scholar
• GilbertJBakerSDBowlingMKA phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignanciesClin Cancer Res2001782292230011489804
   PubMed Web of Science ®Google Scholar
• CamachoLHOlsonJTongWPPhase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumorsInvest New Drugs200725213113817053987
   PubMed Web of Science ®Google Scholar
• GoreSDWengLJZhaiSImpact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaClin Cancer Res20028496397011948101
   PubMed Web of Science ®Google Scholar
• MaslakPChanelSCamachoLHPilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndromeLeukemia200620221221716357841
   PubMed Web of Science ®Google Scholar
• GilbertJBakerSDDonehowerRMethytransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a Phase I study of the MT inhibitor, 5-azacytidine (5AC), and the histone deacetylase inhibitor, phenylbutyrate (PB), in refractory solid tumorsProc Am Soc Clin Onc.200187a
   PubMedGoogle Scholar
• SungMWWaxmanSCombination of cytotoxicdifferentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancerAnticancer Res2007272995100117465233
   PubMed Web of Science ®Google Scholar
• RephaeliARabizadehEAviramADerivatives of butyric acid as potential anti-neoplastic agentsInt J Cancer199149166721874573
   PubMed Web of Science ®Google Scholar
• SchwartzBAvivi-GreenCPolak-CharconSSodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cellsMol Cell Biochem19981881–221309823007
   PubMed Web of Science ®Google Scholar
• MandalMAdamLKumarRRedistribution of activated caspase-3 to the nucleus during butyric acid-induced apoptosisBiochem Biophys Res Commun1999260377578010403841
   PubMed Web of Science ®Google Scholar
• RabizadehEShaklaiMNudelmanARapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrugFEBS Lett199332832252298348968
   PubMed Web of Science ®Google Scholar
• RabizadehEBaireyOAviramADoxorubicin and a butyric acid derivative effectively reduce levels of Bcl-2 protein in the cells of chronic lymphocytic leukemia patientEur J Haematol200166426327111380606
   PubMed Web of Science ®Google Scholar
• PatnaikARowinskyEKVillalonaMAA phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignanciesClin Cancer Res2002872142214812114414
   PubMed Web of Science ®Google Scholar
• ReidTValoneFLiperaWPhase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancerLung Cancer200445338138615301879
   PubMed Web of Science ®Google Scholar
• LoscherWBasic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsyCNS Drugs2002161066969412269861
   PubMed Web of Science ®Google Scholar
• PeruccaEPharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experienceCNS Drugs2002161069571412269862
   PubMed Web of Science ®Google Scholar
• MarchionDCBicakuEDaudAIValproic acid alters chromatin structure by regulation of chromatin modulation proteinsCancer Res20056593815382215867379
   PubMed Web of Science ®Google Scholar
• JungGAYoonJYMoonBSValproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathwayBMC Cell Biol20089667819068119
   PubMedGoogle Scholar
• GottlicherMMinucciSZhuJValproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cellsEMBO J200120246969697811742974
   PubMed Web of Science ®Google Scholar
• GurvichNTsygankovaOMMeinkothJLHistone deacetylase is a target of valproic acid-mediated cellular differentiationCancer Res20046431079108614871841
   PubMed Web of Science ®Google Scholar
• BaconCLGallagherHCHaugheyJCAntiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phaseJ Neurochem2002831121912358724
   PubMed Web of Science ®Google Scholar
• WerlingUSiehlerSLitfinMInduction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivativesMol Pharmacol20015951269127611306712
   PubMed Web of Science ®Google Scholar
• KawagoeRKawagoeHSanoKValproic acid induces apoptosis in human leukemia cells by stimulating both caspase dependent and -independent apoptotic signaling pathwaysLeuk Res200226549550211916526
   PubMed Web of Science ®Google Scholar
• TangRFaussatAMMajdakPValproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1Leukemia20041871246125115116123
   PubMed Web of Science ®Google Scholar
• IchiyamaTOkadaKLiptonJMSodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κBBrain Res20008571–224625110700573
   PubMed Web of Science ®Google Scholar
• SiitonenTKoistinenPSavolainenERIncrease in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cellsLeuk Res200529111335134215936818
   PubMed Web of Science ®Google Scholar
• CiminoGLo-CocoFFenuSSequential valproic acid/Alltrans retinoic acid treatment reprograms differentiation in refractory and highrisk acute myeloid leukemiaCancer Res200666178903891116951208
   PubMed Web of Science ®Google Scholar
• ValentiniAGravinaPFedericiGValproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cellsCancer Biol Ther20076218519117218782
   PubMed Web of Science ®Google Scholar
• AtmacaAAl-BatranSEMaurerAValproic acid (VPA) in patients with refractory advanced cancer: a dose escalating Phase I clinical trialBritish J Cancer2007972177182
   PubMed Web of Science ®Google Scholar
• BugGRitterMWassmannBClinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemiaCancer2005104122717272516294345
   PubMed Web of Science ®Google Scholar
• KuendgenAKnippSFoxFResults of a Phase 2 study of valproic acid alone or in combination with alltrans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemiaAnn Hematol200584Suppl 1616616270213
   PubMed Web of Science ®Google Scholar
• PilatrinoCCilloniDMessaEIncrease in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acidCancer2005104110110915895376
   PubMed Web of Science ®Google Scholar
• RaffouxEChaibiPDombretHValproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemiaHaematologica200590798698815996941
   PubMed Web of Science ®Google Scholar
• DuprezELillehaugJRNaoeTcAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alphaOncogene19961211245124598649787
   PubMed Web of Science ®Google Scholar
• KuendgenASchmidMSchlenkRThe histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemiaCancer2006106111211916323176
   PubMed Web of Science ®Google Scholar
• HuangSBrandtSJmSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factorMol Cell Biol20002062248225910688671
   PubMed Web of Science ®Google Scholar
• WatamotoKTowatariMOzawaYAltered interaction of HDAC5 with GATA-1 during MEL cell differentiationOncogene200322579176918414668799
   PubMed Web of Science ®Google Scholar
• SiitonenTTimonenTJuvonenEValproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromesHaematologica20079281119112217650442
   PubMed Web of Science ®Google Scholar
• SantiniVFerriniPRDifferentiation therapy of myelodysplastic syndromes: fact or fiction?Br J Heamatol1998102511241138
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGKantarjianHMSanchez-GonzalezBPhase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood2006108103271327916882711
   PubMed Web of Science ®Google Scholar
• BlumWKlisovicRBHackansonBPhase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaJ Clin Oncol200725253884389117679729
   PubMed Web of Science ®Google Scholar
• BraitehFSorianoAOGarcia-ManeroGPhase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersClin Cancer Res200814196296630118829512
   PubMed Web of Science ®Google Scholar
• SorianoAOYangHFaderlSSafety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeBlood200711072302230817596541
   PubMed Web of Science ®Google Scholar
• MünsterPMarchionDBicakuEClinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: Phase I/II trial of valproic acid and epirubicin/FECClin Cancer Res20091572488249619318486
   PubMed Web of Science ®Google Scholar
• MünsterPMarchionDBicakuEPhase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational studyJ Clin Oncology2007251519791985
   PubMed Web of Science ®Google Scholar
• DaudAIDawsonJDeContiRCPotentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and Phase I/II clinical trialClin Cancer Res20091572479248919318485
   PubMed Web of Science ®Google Scholar
• RoccaAMinucciSTostiGA Phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanomaBritish J Cancer200910012836
   PubMed Web of Science ®Google Scholar
• FachettiFPrevidiSBallariniMModulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitorsApoptosis20049557358215314285
   PubMed Web of Science ®Google Scholar
• Chavez-BlancoASegura-PachecoBPerez-CardenasEHistone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A Phase I studyMol Cancer2005412216001982
   PubMed Web of Science ®Google Scholar
• CandelariaMGallardo-RinconDArceCA Phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumorsAnn Oncol20071891529153817761710
   PubMed Web of Science ®Google Scholar
• ParulekarWREinsenhauerEANovel endpoints and design of early clinical trialsAnnal Oncol200213Suppl 4139143
   PubMed Web of Science ®Google Scholar
• HunsbergerSRubinsteinLVDanceyJDose escalation trial designs based on a molecularly targeted endpointStat Med200524142171218115909289
   PubMed Web of Science ®Google Scholar
• Segura-PachecoBPerez-CardenasETaja-ChayebLGlobal DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazineJ Transl Med200643216893460
   PubMed Web of Science ®Google Scholar
• RichonVMWebbYMergerRSecond generation hybrid polar compounds are potent inducers of transformed cell differentiationProc Natl Acad Sci U S A19969312570557088650156
   PubMed Web of Science ®Google Scholar
• ButlerLMAgusDBScherHLSuberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivoCancer Res200060785165517011016644
   PubMed Web of Science ®Google Scholar
• FinninMSDonigianJRCohenAStructures of a histone deacetylase homologue bound to the TSA and SAHA inhibitorsNature1999401674918819310490031
   PubMed Web of Science ®Google Scholar
• YinDOngJMHuJSuberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivoClin Cancer Res20071331045105217289901
   PubMed Web of Science ®Google Scholar
• MitsiadesCSPoulakiVMcMullanCNovel histone deacetylase inhibitors in the treatment of thyroid cancerClin Cancer Res200511103958396515897598
   PubMed Web of Science ®Google Scholar
• MunsterPNTroso-SandovalTRosenNThe histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cellsCancer Res200161238492849711731433
   PubMed Web of Science ®Google Scholar
• BaliPPranpatMSwabyRActivity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2Clin Cancer Res200511176382638916144943
   PubMed Web of Science ®Google Scholar
• KomatsuNKawamataNTakeuchiSSAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cellsOncol Rep200615118719116328054
   PubMed Web of Science ®Google Scholar
• ButlerLMAgusDBScherHISuberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivoCancer Res200060185165517011016644
   PubMed Web of Science ®Google Scholar
• DietrichCGreenbergVLDesimoneCPSuberoylanilide hydroxamic acid potentiates paclitaxel-induced apoptosis in ovarian cancer cell linesGynecol Oncol2006116112613019875160
   PubMed Web of Science ®Google Scholar
• KellyWKRichonVMO’ConnorOPhase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenouslyClin Cancer Res.2003910 Pt 13578358814506144
   PubMed Web of Science ®Google Scholar
• KrugLMCurleyTSchwartzLPotential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acidClin Lung Cancer20067425726116512979
   PubMed Web of Science ®Google Scholar
• KellyWKO’ConnorOAKrugLMPhase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancerJ Clin Oncol200523173923393115897550
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGYangnHBueso-RamosCPhase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias andmyelodysplastic syndromesBlood200811131060106617962510
   PubMed Web of Science ®Google Scholar
• ModesittSCSillMHoffmanJSA Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group studyGynecol Oncol2008109218218618295319
   PubMed Web of Science ®Google Scholar
• VansteenkisteJVan CutsemEDumezHEarly Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or nonsmall cell lung cancerInvest New Drugs200826548348818425418
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrKiesMSPapadimitrakopoulouVAPhase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancerInvest New Drugs2008261818717960324
   PubMed Web of Science ®Google Scholar
• LuuTHMorganRJLeongLA phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium studyClin Cancer Res200814217138714218981013
   PubMed Web of Science ®Google Scholar
• GalanisEJaeckleKAMaurerMJPhase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group studyJ Clin Oncol200927122052205819307505
   PubMed Web of Science ®Google Scholar
• WoyachJAKloosRTRingelMDLack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinomaJ Clin Endocrinol Metab200994116417018854394
   PubMed Web of Science ®Google Scholar
• RamalingamSSPariseRARamanathanRKPhase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignanciesClin Cancer Res200713123605361017510206
   PubMed Web of Science ®Google Scholar
• PlumbJAFinnPWWilliamsRJPharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101Mol Cancer Ther20032872172812939461
   PubMed Web of Science ®Google Scholar
• GimsingPBelinostat: a new broad acting antineoplastic histone deacetylase inhibitorExpert Opin Investig Drugs2009184501508
   PubMed Web of Science ®Google Scholar
• GianXLaRochelleWJAraGActivity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studiesMol Cancer Ther2006582086209516928830
   PubMed Web of Science ®Google Scholar
• MonksAHoseCDPezzoliPGene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenograftsAnticancer Drugs200920868269219606018
   PubMed Web of Science ®Google Scholar
• WarrenKEMcCullyCDvingeHPlasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primatesCancer Chemother Pharmacol200862343343717960383
   PubMed Web of Science ®Google Scholar
• TumberACollinsLSPetersenKThe histone deacetylase inhibitor PXD101 synergises with 5-Xuorouracil to inhibit colon cancer cell growth in vitro and in vivoCancer Chemother Pharmacol20076027528317124594
   PubMed Web of Science ®Google Scholar
• SteeleNLPlumbJAVidalLA Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumorsClin Cancer Res200814380481018245542
   PubMed Web of Science ®Google Scholar
• TakadaMKataokaAToiMA close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancerInt J Oncol200425239740515254737
   PubMed Web of Science ®Google Scholar
• GimsingPHansenMKnudsenLMA phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasiaEur J Hematol2008813170176
   PubMed Web of Science ®Google Scholar
• RamalingamSSBelaniCPRuelCPhase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesotheliomaJ Thorac Oncol2009419710119096314
   PubMed Web of Science ®Google Scholar
• MackayHJHirteHColganTPhase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumoursEur J Cancer20104691573157920304628
   PubMed Web of Science ®Google Scholar
• GolayJCuppiniLLeoniFThe histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cellsLeukemia20072191892190017637810
   PubMed Web of Science ®Google Scholar
• VivianiSBonfanteVFasolaCPhase II study of the histonedeacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin’s lymphoma patientsJ Clin Oncol.200826 abstract 8532.
   Web of Science ®Google Scholar
• GalliMSalmoiraghiSGolayJA Phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myelomaAnn Hematol201089218519019633847
   PubMed Web of Science ®Google Scholar
• Carlo-StellaCGuidettiAVivianiSSafety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL)J Clin Oncol.201028 abstract 3068.
   Web of Science ®Google Scholar
• QianDZKatoYShabbeerSTargeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589Clin Cancer Res200612263464216428510
   PubMed Web of Science ®Google Scholar
• PrinceHMBishtonMJJohnstoneRWPanobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumorsFuture Oncol20095560161219519200
   PubMed Web of Science ®Google Scholar
• GilesFFischerTCortesJPhase I Study of Intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesClin Cancer Res200612154628463516899611
   PubMed Web of Science ®Google Scholar
• RathkopfDWongBYRossRWA Phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancerCancer Chemother Pharmacol201066118118920217089
   PubMed Web of Science ®Google Scholar
• RemiszewskiSWThe discovery of NVPLAQ824: from concept to clinicCurr Med Chem200310222393240214529481
   PubMed Web of Science ®Google Scholar
• HurtubiseAMomparlerRLEffect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2-deoxycytidine (decitabine) on human breast carcinoma cellsCancer Chemother Pharmacol200658561862516783580
   PubMed Web of Science ®Google Scholar
• De BonoJSKristeleitRTolcherAPhase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsClin Cancer Res200814206663667318927309
   PubMed Web of Science ®Google Scholar
• KristeleitRSTandyDAtadjaPEffects of the histone deacetylase inhibitor (HDACI) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumours enrolled in a phase I clinical trialJ Clin Oncol.200422 abstract 3023.
   Web of Science ®Google Scholar
• OttmannOGDeangeloDJStoneRMA Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignanciesJ Clin Oncol.200422 abstract 3024.
   Web of Science ®Google Scholar
• ChoyECaoYHornicekFEffect of histone deacetylase inhibitor (HDACI) PCI-24781 on chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell linesJ Clin Oncol.201028 abstract 10089.
   PubMed Web of Science ®Google Scholar
• UndeviaSDJanischLSchilskyRLPhase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781J Clin Oncol.200826 abstract 14514.
   Web of Science ®Google Scholar
• JaboinJWildJHamidiHMS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumorsCancer Res200262216108611512414635
   PubMed Web of Science ®Google Scholar
• LucasDMDavisMEParthunMRThe histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cellsLeukemia20041871207121415116122
   PubMed Web of Science ®Google Scholar
• RosatoRRAlmenaraJAGrantSThe histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1Cancer Res200363133637364512839953
   PubMed Web of Science ®Google Scholar
• LeeBIParkSHKimJWMS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cellsCancer Res200161393193411221885
   PubMed Web of Science ®Google Scholar
• AcharyaMRSparreboomASausvilleEAInterspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitorCancer Chemother Pharmacol200657327528116028097
   PubMed Web of Science ®Google Scholar
• RyanQCHeadleeDAcharyaMPhase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphomaJ Clin Oncol200523173912392215851766
   PubMed Web of Science ®Google Scholar
• KummarSGutierrezMGardnerERPhase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignanciesClin Cancer Res20071318 Pt 15411541717875771
   PubMed Web of Science ®Google Scholar
• GojoIJiemjitATrepelJBPhase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood200710972781279017179232
   PubMed Web of Science ®Google Scholar
• GoreLRothenbergMLO’BryantCLA phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomasClin Cancer Res200814144517452518579665
   PubMed Web of Science ®Google Scholar
• HauschildATrefzerUGarbeCMulticenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanomaMelanoma Res200818427427818626312
   PubMed Web of Science ®Google Scholar
• ZhouNMoradeiORaeppelSDiscovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacethylase inhibitorJ Med Chem200851144072407518570366
   PubMed Web of Science ®Google Scholar
• FournelMBonfilsCHouYMGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivoMol Cancer Ther20087475976818413790
   PubMed Web of Science ®Google Scholar
• SiuLLPiliRDuranIPhase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumorsJ Clin Oncol200826121940194718421048
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGAssoulineSCortesJPhase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemiaBlood2008112498198918495956
   PubMed Web of Science ®Google Scholar
• LancetJENicholsGAssoulineSA Phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS)J Clin Oncol.200725 abstract 2516.
   Web of Science ®Google Scholar
• BociekRGKuruvillaGJProBIsotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)J Clin Oncol.200826 abstract 8507.
   PubMed Web of Science ®Google Scholar
• MartellREYounesAAssoulineSEPhase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinitiation and update of clinical efficacy and safetyJ Clin Oncol.201028 abstract 8086.
   Web of Science ®Google Scholar
• BergerMRBischoffHFritschiESynthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2-aminophenyl) benzamide: a new compound preferentially active in slowly growing tumorsCancer Treat Rep19856912141514243841025
   PubMedGoogle Scholar
• KrakerAJMizzenCAHartlBGModulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinomaMol Cancer Ther20032440140812700284
   PubMed Web of Science ®Google Scholar
• PrakashSFosterBJMeyerMChronic oral administration of CI-994: a Phase 1 studyInvest New Drugs200119111111291827
   PubMed Web of Science ®Google Scholar
• UndeviaSDKindlerHLJanischLA Phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabineAnn Oncol200415111705171115520075
   PubMed Web of Science ®Google Scholar
• RichardsDABoehmKAWaterhouseDMGemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter studyAnn Oncol20061771096110216641168
   PubMed Web of Science ®Google Scholar
• UedaHMandaTMatsumotoSFR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, III: antitumor activities on experimental tumors in miceJ Antibiot19944733153238175484
   PubMed Web of Science ®Google Scholar
• UedaHNakajimaHHoriYFR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activityJ Antibiot19944733013107513682
   PubMed Web of Science ®Google Scholar
• YuXDWangSYChenGAApoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cellsCancer J200713210511317476138
   PubMed Web of Science ®Google Scholar
• SandorVRobbinsARRobeyRFR901228 causes mitotic arrest but does not alter microtubule polymerizationAnticancer Drugs2000111144545411001385
   PubMed Web of Science ®Google Scholar
• SandorVSenderowiczAMertinsSP21-dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228Br J Cancer200083681782510952788
   PubMed Web of Science ®Google Scholar
• WangRBrunnerTZhangLFungal metabolite FR901228 inhibits c-Myc and Fas ligand expressionOncogene19981712150315089794227
   PubMed Web of Science ®Google Scholar
• YuXGuoZSMarcuMGModulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228J Natl Cancer Inst200294750451311929951
   PubMed Web of Science ®Google Scholar
• RajgolikarGChanKKWangHCEffects of a novel antitumor depsipeptide, FR901228, on human breast cancer cellsBreast Cancer Res Treat199851129389877027
   PubMed Web of Science ®Google Scholar
• KitazonoMRobeyRZhanZLow concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na/I symporter and iodine accumulation in poorly differentiated thyroid carcinoma cellsJ Clin Endocrinol Metab20018673430343511443220
   PubMed Web of Science ®Google Scholar
• AronJLParthunMRMarcucciGDepsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP proteinBlood2003102265265812649137
   PubMed Web of Science ®Google Scholar
• WeiserTSGuoZSOhnmachtGASequential 5-aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1J Immunother200124215116111265773
   PubMed Web of Science ®Google Scholar
• SteinerFAHongJAFischetteMRSequential 5-Aza 2-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cellsOncogene200524142386239715735751
   PubMed Web of Science ®Google Scholar
• KlisovicMIMaghrabyEAParthunMRDepsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cellsLeukemia200317235035812592335
   PubMed Web of Science ®Google Scholar
• SasakawaYNaoeYSogoNMarker genes to predict sensitivityto FK228, a histone deacetylase inhibitorBiochem Pharmacol200569460361615670579
   PubMed Web of Science ®Google Scholar
• PiekarzRLFryeRTurnerMPhase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaJ Clin Oncol200927325410541719826128
   PubMed Web of Science ®Google Scholar
• WooSGardnerERChenXPopulation pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphomaClin Cancer Res20091541496150319228751
   PubMed Web of Science ®Google Scholar
• MarshallJLRizviNKauhJA Phase I trial of depsipeptide (FR901228) in patients with advanced cancerJ Exp Ther Oncol20022632533212440223
   PubMedGoogle Scholar
• SandorVBakkesSRobeyRWPhase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasmsClin Cancer Res20028371872811895901
   PubMed Web of Science ®Google Scholar
• ByrdJCMarcucciGParthunMRA phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaBlood2005105395996715466934
   PubMed Web of Science ®Google Scholar
• FouladiMFurmanWLChinTPhase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group reportJ Clin Oncol200624223678368516877737
   PubMed Web of Science ®Google Scholar
• KlimekVMFircanisSMaslakPTolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromesClin Cancer Res200814382683218245545
   PubMed Web of Science ®Google Scholar
• StadlerWMMargolinKFerberSA Phase II study of depsipeptide in refractory metastatic renal cell cancerClin Genitourin Cancer200651576016859580
   PubMed Web of Science ®Google Scholar
• ShahMHBinkleyPChanKCardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumorsClin Cancer Res200612133997400316818698
   PubMed Web of Science ®Google Scholar
• SchrumpDSFischetteMRNguyenDMClinical and molecular responses in lung cancer patients receiving RomidepsinClin Cancer Res200814118819818172270
   PubMed Web of Science ®Google Scholar
• SosmanJAAronsonFRSznolMConcurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicityClin Cancer Res19973139469815535
   PubMed Web of Science ®Google Scholar
• MaloneyAWorkmanPHSP90 as a new therapeutic target for cancer therapy: the story unfoldsExpert Opin Biol Ther20022132411772336
   PubMed Web of Science ®Google Scholar
• BantscheffMHopfCSavitskiMMChemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.Nat Biotechnol.2011 In press.
   Google Scholar